Kalorama: PCR Market Reaches $3.5 Billion
According to Kalorama Information, the total PCR (polymerase chain reaction) technologies market was valued at about $3.5 billion for 2015, up from $3.2 billion in 2013. PCR technologies are increasingly being used for medical testing, specifically in the diagnosis of bacterial disease, detection of antibiotic resistance and diagnosis of infectious disease. They are also being used for cancer exploration of mutations and detection of genetic abnormalities. These technologies, specifically quantitative PCR (qPCR) and digital PCR (dPCR), show significant promise for expanding diagnostic applications. The healthcare market researcher's report, qPCR and dPCR Markets (Instruments, Reagents, Software/Services), analyzes the market for these dynamic technologies in detail.
"qPCR has established itself as the workhorse in the research laboratory," said Bruce Carlson, Publisher of Kalorama Information. "But dPCR's potential is greater in diagnostic applications due to its sensitivity, precision, robustness, and reproducibility."
Polymerase chain reaction is a biochemical technology in molecular biology used to amplify a s
ingle copy or a few copies of a piece of DNA across several orders of magnitude, generating thousands to millions of copies of a particular DNA sequence.
The most notable use of qPCR is DNA sequencing and gene expression in research applications. qPCR is used in a variety of research areas including stem cell research, oncology and genetic disease research, pathogen detection and infectious disease research, and plant sciences research. Other areas of use include forensic science, food and safety applications, and genetically modified organisms (GMO) testing. qPCR is utilized as well to detect genetic abnormalities and cancer mutations. qPCR-based diagnostic tests are expected to expand in the coming years.
dPCR provides absolute measurement of copies and would seem to be the next logical step in PCR evolution. dPCR partitions sample and reaction components into hundreds or thousands of reaction chambers to count the presence or absence of molecules. It provides greatly improved sensitivity in the detection of rare mutations and sequences. This technology will become increasingly important as clinical applications evolve.
Competition in the PCR technology market is steadily escalating in the United States and Europe, which is in turn encouraging more participation in other areas such as Asia and Latin America. There are numerous companies in the market, including large multiproduct companies such as Thermo Fisher Scientific, Roche, and Abbott, as well as small niche developers such as RainDance Technologies.
"We look at over two dozen companies in our report," said Carlson. "Competitive activity is high in this market."
qPCR and dPCR Markets contains essential market information for business planning and strategy, including the following: qPCR market, 2015-2020; dPCR market, 2015-2020; market by product type (reagents, instruments, software services, total, percent change); market share by use, 2015 (clinical, research, other); market share by geographic region, 2013 (U.S., Europe, Japan, ROW); selected qPCR and dPCR-based molecular tests in development; company profiles; overview of product offerings; regulatory structure and background information; and trends in the qPCR and dPCR markets.
The report provides detailed market sizing and forecasts for both the research and clinical PCR market to 2020. Trends are discussed, competitors profiled, and useful business planning data provided. The report estimates markets and forecasts markets for reagents, instruments, and the software/services used in PCR. Regions covered include: United States, Europe, Asia and the rest of the world.
